US FDA Tech Modernization Plan’s Costs Uncertain
Executive Summary
Agency officials determining needs using existing budgets before requesting more funds and will engage with tech investors for design advice.
You may also be interested in...
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
BsUFA III Talks Could Move Cloud-Platform Goals Forward
US FDA wants to use biosimilars for a demonstration of cloud-based technology, an idea mentioned to increase the use of real-time review and enhance data analysis.
US FDA’s Data Strategy Under Increasing Pressure From Coronavirus Pandemic
As agency prepares to hear from stakeholders on its strategy, real-world data precedents already are being set thanks to COVID-19, Aetion tells the Pink Sheet.